Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study.

Diabet Med · 2010 · PMC2948428 · PMID 20536952

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an apparent trendno p-value reported

Despite the short treatment duration of the current study, there was a reduction in body weight in all groups studied, including placebo, with an apparent trend towards greater weight loss in the 20/30- and 20/40-mg groups.

also in 709 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.